PinnyPeptide

MOTS-c vs NAD+ (Injectable)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

MOTS-c

Longevity

Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis.

Peptide B

NAD+ (Injectable)

Longevity

Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity.

Typical vial

5 mg

Typical dose

5000-10000 mcg

Half-life

Not well characterized in humans (estimated hours based on peptide size)

FDA status

Not FDA approved. Investigational compound with no clinical …

Typical vial

500 mg

Typical dose

50-200 mg (SubQ); 500-1500 mg (IV) mcg

Half-life

~6-10 hours (cellular turnover)

FDA status

Not FDA approved as a therapeutic. Available via compounding…

MOTS-c effects

  • Activates AMPK pathway to enhance metabolic homeostasis
  • Improves insulin sensitivity and glucose uptake
  • Promotes fatty acid oxidation and reduces fat accumulation
  • Mimics exercise-induced metabolic adaptations
  • Preserves skeletal muscle function during aging
  • Enhances mitochondrial biogenesis and function

NAD+ (Injectable) effects

  • Raises cellular NAD+ levels
  • Supports mitochondrial function via electron transport chain
  • Substrate for sirtuin enzymes (deacetylases linked to longevity)
  • Substrate for PARP enzymes (DNA repair)
  • Substrate for CD38 (immune signaling)
  • Subjective reports of energy, mental clarity, mood

MOTS-c side effects

  • Injection site reactions (redness, mild pain)
  • Transient changes in blood glucose levels
  • Mild fatigue during initial dosing
  • Limited human safety data available

NAD+ (Injectable) side effects

  • Flushing during IV infusion (most common, mild)
  • Nausea, chest pressure, abdominal discomfort with rapid infusion
  • Headache
  • Subcutaneous: injection-site irritation
  • Possible methylation depletion with chronic high doses

MOTS-c dosing ranges

Metabolic optimization and longevity

5-10 mg · Three to five times weekly (SubQ) · 4-8 weeks

NAD+ (Injectable) dosing ranges

IV anti-aging clinic protocol

500-1500 mg · Per infusion, weekly to monthly · Cycle-based

Subcutaneous wellness

50-200 mg · Daily or alternate-day · 2-4 week cycles

Intranasal

20-100 mg · Daily · Cycle-based

MOTS-c vs NAD+ (Injectable) — common questions

What is the difference between MOTS-c and NAD+ (Injectable)?

MOTS-c: Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis. Typical dose 5000-10000 mcg. NAD+ (Injectable): Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity. Typical dose 50-200 mg (SubQ); 500-1500 mg (IV) mcg. Both fall under the Longevity category.

Can you stack MOTS-c and NAD+ (Injectable)?

Stacking MOTS-c with NAD+ (Injectable) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, MOTS-c or NAD+ (Injectable)?

MOTS-c is typically dosed: Three to five times weekly (SubQ) for Metabolic optimization and longevity. NAD+ (Injectable) is typically dosed: Per infusion, weekly to monthly for IV anti-aging clinic protocol; Daily or alternate-day for Subcutaneous wellness; Daily for Intranasal.

Are MOTS-c and NAD+ (Injectable) FDA approved?

MOTS-c: Not FDA approved. Investigational compound with no clinical trials completed for regulatory submission. NAD+ (Injectable): Not FDA approved as a therapeutic. Available via compounding pharmacies for off-label use. NAD+ precursors (NR as Niagen, NMN) sold as dietary supplements.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free